湖南中医药大学学报2017，Vol.37Issue(7)：778-780,3.DOI:10.3969/j.issn.1674-070X.2017.07.021
黄连饮片制剂的临床安全性研究
Study on Clinical Safety of Rhizoma Coptidis Preparations
摘要
Abstract
Objective To investigate the dosage compatibility and the clinical safety of rhizoma coptidis preparations and provide the reference for clinical medication. Methods The general information, medication situation, alanine aminotransferase (ALT) and aspartate amino transferase of 96 cases patients used rhizoma coptidis in our hospital from August 2014 to July 2016. were. Results Among 96 cases of patients, the number of male patients was 54, the number of female patients was 42. 71 cases of patients were treated with decoction therapy (73.96%), 13 cases of patients were treated with water pill therapy (13.54%), 8 cases of patients were treated with pellet therapy (8.33%), 4 cases of patients were treated with powder (4.17%). Male patients' daily doses of rhizoma coptidis were obviously higher than that of female patients (P<0.05). Male patients' course, total dosages of rhizoma coptidis were significantly lower than those of female patients (P<0.05). ALT and AST of 5 patients showed changes, the change rate was 7.29%. Adverse reactions happened in 7 cases of patientst the adverse reaction rate was 9.38%. Conclusion It will not show too many adverse reactions in the treatment of diseases with rhizoma coptidis preparations in general. But for the patients with impaired liver function, the level of ALT and AST will increase to some ex-tent after taking of rhizoma coptidis and compatibility medications, which could improve the clinical safety of compatibili-ty medications.关键词
黄连饮片/不良反应/ALT/AST/用量配伍/临床安全性Key words
rhizoma coptidis pieces/adverse reaction/ALT/AST/dosage compatibility/clinical safety分类
医药卫生引用本文复制引用
张结军..黄连饮片制剂的临床安全性研究[J].湖南中医药大学学报,2017,37(7):778-780,3.基金项目
四川省科技厅科研基金项目(2015JY0264). （2015JY0264）
